Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies
出版年份 2020 全文链接
标题
Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies
作者
关键词
-
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-09-03
DOI
10.1007/s00262-020-02712-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients
- (2020) Edwin A. Basak et al. THYROID
- Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
- (2019) Tomomi Nobashi et al. CLINICAL NUCLEAR MEDICINE
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
- (2019) Ichiro Yamauchi et al. PLoS One
- Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients
- (2019) Nina Lang et al. Immunotherapy
- THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW.
- (2019) Mazen Al Mushref et al. Endocrine Practice
- Good clinical practice recommendations for the use of PET/CT in oncology
- (2019) Pierre-Yves Salaün et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
- (2019) Anupam Kotwal et al. THYROID
- Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
- (2018) Ahmed Mekki et al. EUROPEAN JOURNAL OF CANCER
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Expert opinion on thyroid complications in immunotherapy
- (2018) Frederic Illouz et al. ANNALES D ENDOCRINOLOGIE
- Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
- (2018) Priyanka C. Iyer et al. THYROID
- Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
- (2018) Christos Sachpekidis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- FDG PET/CT for assessing tumour response to immunotherapy
- (2018) Nicolas Aide et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
- (2018) Christos Sachpekidis et al. MELANOMA RESEARCH
- Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
- (2017) Hoda Anwar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms
- (2017) M. Alhusseini et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
- (2017) Hyunju Lee et al. Cancer Immunology Research
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
- (2016) Jeroen de Filette et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody Therapy
- (2011) Yulia Bronstein et al. AMERICAN JOURNAL OF ROENTGENOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now